Back to Search
Start Over
[Differences among renin-angiotensin system inhibitor drugs in prognosis of hypertense patients with COVID-19].
- Source :
-
Archivos de cardiologia de Mexico [Arch Cardiol Mex] 2022 Apr 07; Vol. 93 (Supl 6), pp. 58-65. Date of Electronic Publication: 2022 Apr 07. - Publication Year :
- 2022
-
Abstract
- Introduction: Concerns have been raised about Renin-angiotensin system inhibitors (RASi) in patients with COVID-19. Although recent trials have proved its security, evidence regarding intrinsic differences between RASi is lacking, especially in patients with arterial hypertension. Our objective was to analyse the prognosis of hypertense patients who received angiotensin converting enzyme inhibitors (ACEi) or angiotensin-2 receptor blockers (ARBs) and were hospitalized due to COVID-19.<br />Materials and Methods: 392 consecutive patients with hypertension and COVID-19 were analyse. Incidence of the combined event (death or mechanical ventilation need) was the primary endpoint. Secondary, incidence of each event and time to event were analysed.<br />Results: 155 received ACEi and 237 ARBs. During the hospitalization, the combined event was observed in the 31,6 % of patients. No differences were observed between those previously treated with ACEi and ARBs (33.5 vs. 30.9%; p = 0.51). In the survival analysis, no differences were observed regarding time to combined event (p = 0.91). In-hospital mortality was similar in both groups (32.3 vs. 29.1%; p = 0.51), as well as the need of mechanical ventilation (3.2 vs. 5.9%; p = 0.23).<br />Conclusions: The type of RASi was not associated with in-hospital major events in patients with arterial hypertension hospitalized due to COVID-19.
Details
- Language :
- Spanish; Castilian
- ISSN :
- 1665-1731
- Volume :
- 93
- Issue :
- Supl 6
- Database :
- MEDLINE
- Journal :
- Archivos de cardiologia de Mexico
- Publication Type :
- Academic Journal
- Accession number :
- 35389602
- Full Text :
- https://doi.org/10.24875/ACM.21000185